Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $11.00.

Several equities analysts have recently issued reports on AQST shares. JMP Securities reaffirmed a "market outperform" rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Leerink Partners increased their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Finally, Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an "overweight" rating and a $17.00 target price on the stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company's stock valued at $7,454,000 after purchasing an additional 512,682 shares in the last quarter. Blue Owl Capital Holdings LP raised its position in Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company's stock valued at $2,964,000 after buying an additional 265,000 shares during the period. Bank of New York Mellon Corp purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth about $594,000. Verition Fund Management LLC acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth about $995,000. Finally, Wellington Management Group LLP acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth about $922,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Stock Up 6.2 %

NASDAQ AQST traded up $0.19 on Wednesday, reaching $3.24. 1,245,753 shares of the stock traded hands, compared to its average volume of 1,759,716. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23. The firm's fifty day simple moving average is $4.06 and its 200 day simple moving average is $4.17. The company has a market cap of $295.42 million, a price-to-earnings ratio of -7.20 and a beta of 2.71.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the company earned ($0.03) earnings per share. As a group, equities research analysts forecast that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.